What’s the current market cap for Danaher stock?

Danaher (DHR) has a market cap of $139bn as of June 28, 2026.

What is the P/E ratio for Danaher stock?

The price to earnings (P/E) ratio for Danaher (DHR) stock is 37.89 as of June 28, 2026.

Does Danaher stock pay dividends?

Yes, the Danaher (DHR) stock pays dividends to shareholders. As of June 28, 2026, the dividend rate is $1.36 and the yield is 0.82%. Danaher has a payout ratio of 24.67% on a trailing twelve-month basis.

When is the next Danaher dividend payment date?

The next Danaher (DHR) dividend payment is scheduled for July 31, 2026.

What is the beta indicator for Danaher?

Danaher (DHR) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Danaher stock | $DHR Share Price

13:30

15:10

16:45

18:25

20:00

About Danaher

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Ticker

$DHR

Sector

Health

Primary listing

NYSE

Employees

59,000

Headquarters

Washington, United States

Website

www.danaher.com

Danaher Metrics

BasicAdvanced

$139bn

37.89

$5.18

0.84

$1.36

0.82%

What the Analysts think about Danaher

Analyst ratings (Buy, Hold, Sell) for Danaher stock.

Bulls say / Bears say

Danaher topped first-quarter profit expectations with non-GAAP EPS of $2.06, up 9.5% year-over-year, driven by 7% core sales growth in its Cytiva bioprocessing segment (Reuters).

Danaher’s February agreement to acquire Masimo for $9.9 billion expands its diagnostics portfolio and is expected to yield over $125 million in annual cost synergies and $50 million in revenue synergies by the fifth year post-close (El País).

The company raised its full-year 2026 adjusted diluted EPS guidance to $8.35–$8.55, up from $8.35–$8.50, reflecting confidence in margin expansion and cash flow generation (PR Newswire).

Core sales in Danaher’s Diagnostics segment fell 4% year-over-year in Q1 2026, highlighting ongoing headwinds in its largest revenue segment (PR Newswire).

Life Sciences Tools core revenue grew just 0.5% in Q1 2026, signalling lacklustre demand in a segment comprising nearly 30% of net sales (PR Newswire).

The $9.9 billion Masimo acquisition increases leverage and integration complexity, potentially pressuring free cash flow and credit metrics if targeted synergies are delayed (Investing.com).

Data summarised monthly by Lightyear AI. Last updated on 27 Jun 2026.

Danaher Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Danaher Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.